Development of a method for the analysis of the lists of medicines and its application for the analysis of the lists of medicines in Russia, England, and Italy

Development of a method for the analysis of the lists of medicines and its application for the analysis of the lists of medicines in Russia, England, and Italy

Objective: the development and approbation of the method for comparative analysis of the lists of medicines in different countries and systems of healthcare.Material and methods. Based on the open-access data on the lists of medicines published on official websites of the authorized regulators, the...

Full description

Bibliographic Details
Main Authors:	V. A. Lemeshko, K. I. Matrenin, V. V. Omelyanovskiy, Yu. V. Vasilyeva, G. R. Khachatryan, L. A. Kolganov
Format:	Article
Language:	Russian
Published:	IRBIS LLC 2021-04-01
Series:	Фармакоэкономика
Subjects:	lists of medicines anatomical therapeutic chemical classification drug provision vital and essential medicines system of reimbursement
Online Access:	https://www.pharmacoeconomics.ru/jour/article/view/482

Similar Items

Evaluation of alignment of the reimbursement medicines list for children in Albania with the WHO essential medicines list for children
by: E. Petro, et al.
Published: (2024-12-01)

A comparative analysis of the Libyan national essential medicines list and the WHO model list of essential medicines
by: Asma Abubakr Mustafa, et al.
Published: (2010-12-01)

National Essential Medicines List and policy practice: A case study of China’s health care reform
by: Tian Xin, et al.
Published: (2012-11-01)

Comparative analysis of the range list of medicines for the treatment of arterial hypertension in accordance with domestic and international clinical guidelines
by: N. V. Sholoiko, et al.
Published: (2022-02-01)

The concept of multi-criteria analysis of decision-making in the current system of health technology assessment in Russia
by: V. V. Omelyanovsky, et al.
Published: (2018-11-01)

The Consistency Between the Chinese Essential Medicines List and Treatment Guidelines—Taking Oncology Medicines as an Example
by: Luyan Cheng, et al.
Published: (2022-07-01)

The revision of the restrictive lists of medicinal products
by: B. K. Romanov, et al.
Published: (2018-02-01)

Improvements to the formation of lists of drugs for medical use: analysis of changes in the Government Decree no. 871
by: V. V. Omelyanovskiy, et al.
Published: (2020-08-01)

Analysis of dynamics of the medcine list in the government program «available medicines» for treatment of bronchial asthma
by: I. A. Kostiuk
Published: (2019-10-01)

Health technology assessment and reimbursement of pharmaceuticals in Italy
by: F. V. Gorkavenko, et al.
Published: (2019-07-01)

The “Square Box”: Therapeutic Equivalence as a Foundation of the WHO Model List of Essential Medicines
by: Bernadette Cappello, et al.
Published: (2020-09-01)

Analysis of dynamics of the drug list in the аffordable medicines program for treatment of cardiovascular diseases
by: V. S. Huz, et al.
Published: (2019-03-01)

Assessment of Iran Medicine List for the Appropriateness of the Six Pharmacological Formulations for Children's Prescription: A Cross Sectional Study
by: Minoo Boroumand, et al.
Published: (2019-08-01)

Access to Cardiovascular Disease and Hypertension Medicines in Developing Countries: An Analysis of Essential Medicine Lists, Price, Availability, and Affordability
by: Muhammad Jami Husain, et al.
Published: (2020-05-01)

Adoption of the governmental affordable medicines programme by ukrainians.
by: M. V. Shevchenko, et al.
Published: (2020-07-01)

Reimbursement process of medicinal products in Poland and in the world
by: Aneta Katarzyna Mela
Published: (2020-09-01)

Biologic medicine inclusion in 138 national essential medicines lists
by: Raphaël Kraus, et al.
Published: (2021-09-01)

The health technology assessment system in Australia
by: V. V. Omelyanovskiy, et al.
Published: (2020-02-01)

Costs and Evaluation of Vital and Essential Medicines for Internal Diseases Treatment, Purchased by Medical Organizations with the Funding from the System of Obligatory Medical Insurance in 2017
by: O. M. Drapkina, et al.
Published: (2019-11-01)

Costs and Evaluation of Vital and Essential Medicines for Internal Diseases Treatment, Purchased by Medical Organizations with the Funding from the System of Obligatory Medical Insurance in 2017
by: O. M. Drapkina, et al.
Published: (2019-11-01)

Assessing the Appropriateness of Formulations on the WHO Model List of Essential Medicines for Children: Development of a Paediatric Quality Target Product Profile Tool
by: Jennifer Walsh, et al.
Published: (2022-02-01)

Essential medicines for mental disorders: comparison of 121 national lists with WHO recommendations
by: Beatrice Todesco, et al.
Published: (2023-01-01)

Cost analysis of different antibiotic brands available in indian market with reference to National List of Essential Medicines
by: Dinesh Kumar Meena, et al.
Published: (2021-01-01)

MATHEMATICAL MODEL OF REIMBURSEMENT DECISION MAKING IN RUSSIA. RESULTS OF VIM LIST FOR 2016
by: A. S. Kolbin, et al.
Published: (2016-04-01)

Analysis of the domestic list of otc medicines and development of approaches to its improvement
by: L. O. Hala, et al.
Published: (2022-08-01)

Essential medicine list in India, 2022: A recent update
by: U. Sharath, et al.
Published: (2023-01-01)

WADA Prohibited List: The Benefits of Combining Pharmacology, Medicine, and Law
by: Ahmad Saad Ahmad AL-Dafrawi
Published: (2022-12-01)

Analysis of the dynamics of the nomenclature of medicines in the government program «Available medicines»
by: І. А. Кostiuk, et al.
Published: (2022-06-01)

Evaluation of prescriptions of medicines not included in Iran medicine list: A cross-sectional study
by: Marzieh Zargaran, et al.
Published: (2016-01-01)

Retrospective analysis of prescriptions for the treatment of cardiovascular diseases in the program «Affordable medicines» on the example of a pharmacy
by: V. S. Huz, et al.
Published: (2020-10-01)

Analysis of organizational and medical documents and formulary lists regulating medical support of pregnant women
by: M. L. Syatynya, et al.
Published: (2012-12-01)

A quantitative comparison of essential cardiovascular medicines from countries in the Southern African Development Community to the WHO model essential medicines list
by: Ian Naicker, et al.
Published: (2022-12-01)

Pharmaceutical pricing and reimbursement policies: perspectives for the future
by: Andrew L Gray
Published: (2015-12-01)

Bridging the gap? Local production of medicines on the national essential medicine lists of Kenya, Tanzania and Uganda
by: Ayo-Oley Baldeh, et al.
Published: (2023-01-01)

Herbal and traditional Herbal Medicinal Products, EU Herbal monographs and EU list
by: Petrović Silvana
Published: (2019-01-01)

Economic evaluation in stratified medicine: methodological issues and challenges
by: Hans-Joerg eFugel, et al.
Published: (2016-05-01)

Access to innovative drugs and the National Reimbursement Drug List in China: Changing dynamics and future trends in pricing and reimbursement
by: Bérengère Macabeo, et al.
Published: (2023-12-01)

Factors Influencing Delays in Patient Access to New Medicines in Canada: A Retrospective Study of Reimbursement Processes in Public Drug Plans
by: Sam Salek, et al.
Published: (2019-03-01)

Exploring pharmacists' perspectives on preparing discharge medicine lists: A qualitative study
by: Helena Gjone, et al.
Published: (2023-03-01)

Evaluating the implementation of the standard treatment guidelines (STGs) and essential medicines list (EML) at a public South African tertiary institution and its associated primary health care (PHC) facilities
by: Tashni Govender, et al.
Published: (2021-12-01)